Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery.

Autor: Lund LH; Unit of Cardiology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Crespo-Leiro MG; Department of Cardiology, Hospital Universitario A Coruña (CHUAC), A Coruña, Spain.; Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.; Fisioterapia, Medicina y Ciencias Biomédicas, Universidad de A Coruña (UDC), A Coruña, Spain.; Instituto Investigación Biomedica A Coruña (INIBIC), A Coruña, Spain., Laroche C; EURObservational Research Programme, European Society of Cardiology, Sophia Antipolis, France., Garcia-Pinilla JM; Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.; Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, Málaga Biomedical Research Institute (IBIMA), Málaga, Spain.; Departamento de Medicina y Dermatología, Universidad de Málaga, Málaga, Spain., Bennis A; Department of Cardiology, Ibn Rochd University Center, Casablanca, Morocco., Vataman EB; Heart Failure Department, Institute of Cardiology, Chișinău, Moldova.; Cardiac Rehabilitation Department, Institute of Cardiology, Chișinău, Moldova., Polovina M; Department of Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia.; Faculty of Medicine, Belgrade University, Belgrade, Serbia., Radovanovic S; Department of Cardiology, Heart Failure Center, University Hospital Center 'Dr Dragisa Misovic-Dedinje', Belgrade, Serbia., Apostolovic SR; Department of Cardiology, University Clinical Centre of Serbia, Nis, Serbia.; Medical School, University Clinical Centre of Serbia, Nis, Serbia., Ašanin M; Department of Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia.; Faculty of Medicine, Belgrade University, Belgrade, Serbia., Gackowski A; Department of Coronary Disease and Heart Failure, Jagiellonian University, Medical College, John Paul II Hospital, Krakow, Poland.; Noninvasive Cardiovascular Laboratory, John Paul II Hospital, Krakow, Poland., Kaplon-Cieslicka A; 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland., Cabac-Pogorevici I; Department of Cardiology, State University of Medicine and Pharmacy 'Nicolae Testemitanu', Chișinău, Moldova., Anker SD; Department of Cardiology (CVK) of German Heart Center Charité, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland., Chioncel O; 1st Cardiology Department, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', Bucharest, Romania.; University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania., Coats AJS; Office of the CEO, Heart Research Institute, Sydney, NSW, Australia., Filippatos G; Department of Cardiology, National and Kapodistrian, University of Athens, Athens, Greece., Lainscak M; Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Mcdonagh T; Cardiovascular Science, Faculty of Life Science and Medicine, King's College London, London, UK., Mebazaa A; Anaethesia and Critical Care, APHP, Hôpital Lariboisière, Paris, France.; Burn and the multi-organ retrieval, APHP, Hôpital Saint Louis, Paris, France.; Cardiovascular MArkers in Stressed COndiTions, UMRS INSERM 942, Université Paris-Cité, Paris, France., Metra M; Department of Cardiology, Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.; Department of Cardiology, ASST Spedali Civili, Brescia, Italy., Piepoli M; Clinical Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Italy.; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy., Rosano GM; Department of Medical Sciences, IRCCS Ospedale San Raffaele, Rome, Italy., Ruschitzka F; Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.; Department of Cardiology, Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich and University of Zurich, Zurich, Switzerland., Savarese G; Unit of Cardiology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.; Heart and Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden., Seferović PM; Faculty of Medicine, Belgrade University, Belgrade, Serbia.; Serbian Academy of Sciences and Arts, Belgrade, Serbia., Iung B; Department of Cardiology, APHP, Hôpital Bichat Claude-Bernard, Paris, France.; LVTS INSERM 1148, Université Paris-Cité, Paris, France., Popescu BA; Department of Cardiology, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.; Department of Cardiology, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', Bucharest, Romania., Maggioni AP; ANMCO Research Center, Heart Care Foundation, Florence, Italy.
Jazyk: angličtina
Zdroj: European journal of heart failure [Eur J Heart Fail] 2023 Dec; Vol. 25 (12), pp. 2316-2330. Date of Electronic Publication: 2023 Nov 29.
DOI: 10.1002/ejhf.3087
Abstrakt: Aims: Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Methods: Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes.
Conclusion: The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy.
(© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje